PAP
COGT icon

Persistent Asset Partners’s Cogent Biosciences COGT Stock Holding History

Persistent Asset Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-59,797
Closed -$223K – 256
2025
Q2 		$223K Buy
59,797
+59,318
+12,384% +$329K 0.17% 109
2025
Q1 		$72K Buy
+479
New +$3.76K 0.06% 122

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Persistent Asset Partners's COGT Position: Q2 2026 in Review

Persistent Asset Partners increased its Cogent Biosciences (COGT) stake by 49% in Q2 2026, buying an estimated $1.6M and bringing the position to 138,272 shares worth $5.35M. The position accounts for 1.6% of the portfolio, ranked #12.

Persistent Asset Partners first reported a position in COGT in Q4 2024 and has held it in 7 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Persistent Asset Partners held 138,272 shares of Cogent Biosciences worth $5.35M as of Q2 2026.
  • Persistent Asset Partners bought 45,756 Cogent Biosciences shares in Q2 2026, an estimated $1.6M.
  • Cogent Biosciences made up 1.6% of Persistent Asset Partners's portfolio in Q2 2026, its #12 holding.
  • Persistent Asset Partners first reported a position in Cogent Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.